X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CFI-400945 (ocifisertib) is a first-in-class, investigational PLK4 inhibitor. It is being evaluated for the treatment of relapsed/refractory acute myeloid leukemia.
Lead Product(s): CFI-400945,Azacitidine
Therapeutic Area: Oncology Product Name: CFI-400945
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
CFI-402257, a best in class inhibitor of Threonine Tyrosine Kinase (TTK, also known as Mps1), for the treatment of adult patients with ER+/HER2- advanced breast cancer after disease progression on prior CDK4/6 inhibitors and endocrine therapy.
Lead Product(s): CFI-402257,Fulvestrant
Therapeutic Area: Oncology Product Name: CFI-402257
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
CFI-400945, a first in class inhibitor of Polo-like kinase 4 (PLK4), for the treatment of adult patients with relapsed or refractory Acute Myeloid Leukemia, has shown encouraging signs of monotherapy activity in AML patients with adverse cytogenetics.
Lead Product(s): CFI-400945,Azacitidine
Therapeutic Area: Oncology Product Name: CFI-400945
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
Proceeds will fund the continued clinical development of CFI-400945, CFI-402257 and CFI-402411, the preclinical development of the Biologics and Cell Therapy platform, as well as general corporate purposes.
Lead Product(s): CFI-400945,Azacitidine
Therapeutic Area: Oncology Product Name: CFI-400945
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sino Biopharmaceutical Limited
Deal Size: $91.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 18, 2021
Details:
Currently available approaches of autologous TCR-based cell therapy focus on TCRs recognizing HLA-A2 restricted epitopes, alleles well represented in Caucasian populations.
Lead Product(s): Autologous TCR-based Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: TCRyption Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 15, 2021
Details:
The trial is built on the preclinical work demonstrating an association between loss of the tumor suppressor PTEN, a common alteration in this disease setting, and response to CFI-400945.
Lead Product(s): CFI-400945
Therapeutic Area: Oncology Product Name: CFI-400945
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
Treadwell has started patient dosing in TWT-101, its Phase 1/2 study to evaluate CFI-402411, an oral, first-in-class inhibitor of hematopoietic progenitor kinase 1 in patients with solid tumors as a monotherapy or in combination with PD1 pathway blockade.
Lead Product(s): CFI-402411,Pembrolizumab
Therapeutic Area: Oncology Product Name: CFI-402411
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Details:
The expansion cohorts include ER+/HER2 breast cancer patients in combination with fulvestrant post CDK4/6 inhibitor failure, triple negative breast cancer patients and an additional cohort in solid tumors.
Lead Product(s): CFI-402257,Fulvestrant
Therapeutic Area: Oncology Product Name: CFI-402257
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
This multi-center, single-arm, open-label phase 2 trial is designed to assess the efficacy of CFI-400945 given with durvalumab in patients with treatment-resistant TNBC.
Lead Product(s): CFI-400945,Durvalumab
Therapeutic Area: Oncology Product Name: CFI-400945
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
Treadwell intends to initiate a Phase 1/2 clinical trial of CFI-402411, designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CFI-402411 and to determine optimal dosing as a monotherapy and in combination with PD1 pathway inhibitors.
Lead Product(s): CFI-402411
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
